GlaxoSmithKline Pharma's stock is now rated 'Sell', reflecting a bearish outlook, owing to the decline in its technical momentum and prevailing concerns. Investors should reconsider their holdings due to these factors.

GSK Pharma's fourth-quarter profits climbed by 5.7% year-on-year, while revenue also saw a growth of 2.2%. These positive figures suggest a promising end to the year for the pharmaceutical giant.

GSK Pharma declared a dividend of INR 57 per share following Q4 results, indicating a 5.7% increase in profit to INR 278 crore. Despite strong earnings before interest, taxes, depreciation, and amortization (Ebitda) margin of 35.3%, the stock price dipped by 1.52% to INR 2411.70, possibly due to factors other than financial performance.

GlaxoSmithKline Pharma's first quarter results for fiscal year 2026 show no growth compared to the previous quarter, marking a departure from their growth trend. This has resulted in a halt in revenue progression and margin widening, as indicated by a financial trend score of zero over the past three months.

GlaxoSmithKline Pharma's financial year 2026 performance showed a 10% increase in profit after tax, reaching INR 1012 crores, despite a 2% drop in revenue to INR 3790 crores. The company also expanded its EBITDA margin by 290 basis points to 34%. They have proposed a dividend of Rs. 57 per share and reported strong growth in their oncology portfolio.

GSK Pharma has announced a share dividend of INR 57 per share, providing shareholders with a potential payout.

GSK Pharma's Q4 revenue increased by 2.6% year-on-year, reaching 10 billion INR, but fell slightly short of last year's 9.74 billion mark.

GlaxoSmithKline Pharma is set to convene a board meeting on May 13, 2026, where they'll evaluate and approve the FY26 financial results. The discussion will also include potential recommendations for a dividend payment for equity shareholders.

GlaxoSmithKline Pharma's recent downturn has led MarketsMojo to downgrade the stock to 'Sell', reflecting a negative shift in technical indicators and raising performance concerns.

GlaxoSmithKline Pharma has been hit with a tax demand of INR 2 crores for the fiscal year 2020-21, consisting primarily of INR 1.11 crores in TDS and INR 0.90 crores in interest. The company plans to appeal this decision.